FINWIRES · TerminalLIVE
FINWIRES

Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer

By

Telomir Pharmaceuticals (TELO) said Thursday the US Food and Drug Administration has approved its investigational new drug application for its lead candidate Telomir-Zn to treat people with advanced or metastatic triple-negative breast cancer.

The clearance will allow the company to advance Telomir-Zn into clinical evaluation, Telomir said, adding it plans to start the first-in-human phase 1/2 trial in H1.

Telomir shares were down over 2% in Thursday morning trading.

Price: $1.43, Change: $-0.02, Percent Change: -1.38%

Related Articles

Wire

Cheesecake Factory Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Cheesecake Factory (CAKE) reported Q1 adjusted earnings late Wednesday of $1.05 per diluted share, up from $0.93 a year earlier.Analysts polled by FactSet expected $1.01.Revenue in the 13 weeks ended March 31 rose to $978.8 million from $927.2 million a year earlier.Analysts surveyed by FactSet expected $964.6 million.Cheesecake Factory shares rose 4.7% in after-hours trading.

$CAKE
Wire

Pilgrim's Pride Q1 Adjusted Earnings Fall, Sales Rise

Pilgrim's Pride (PPC) reported Q1 adjusted earnings late Wednesday of $0.51 per diluted share, down from $1.31 a year earlier.Analysts polled by FactSet expected $0.65.Net sales for the quarter ended March 29 rose to $4.53 billion from $4.46 billion a year earlier.Analysts surveyed by FactSet expected $4.43 billion.

$PPC
Wire

National Fuel Gas Fiscal Q2 Adjusted Earnings, Revenue Rise

National Fuel Gas (NFG) reported fiscal Q2 adjusted earnings late Wednesday of $2.71 per diluted share, up from $2.39 a year earlier.Analysts polled by FactSet expected $2.84.Revenue for the three months ended March 31 was $858.4 million, up from $730 million a year earlier.Analysts surveyed by FactSet expected $856.6 million.The company revised its fiscal 2026 adjusted EPS guidance range to $7.45 to $7.75 from $7.60 to $8.10 earlier. Analysts expect $7.79.

$NFG